

SmartPA Criteria Proposal

| | |
|-----------------------------------|--|
| Drug/Drug Class: | Psychotropic Medications Polypharmacy Clinical Edit |
| First Implementation Date: | November 5, 2010 |
| Proposed Date: | October 17, 2023 |
| Prepared for: | MO HealthNet |
| Prepared by: | MO HealthNet/Conduent |
| Criteria Status: | <input type="checkbox"/> Existing Criteria <input checked="" type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria |

Executive Summary

Purpose: Ensure appropriate and prudent use psychotropic medications

Why Issue Selected: MO HealthNet will assess the usage of psychotropic agents in the pharmacy program with a primary goal of patient safety in regard to polypharmacy or use of more drugs than is medically necessary. Participants may have multiple prescribers and/or multiple pharmacies caring for them, and, by using medical evidence guidelines, this clinical edit can flag potentially dangerous duplication within drug classes, dangerous drug interactions, or overmedication. The edit helps to provide an “early warning alert” to the pharmacist filling the prescription and the prescribing physician. As always, if a provider wishes to override a denial for medically necessary reasons, a claim can be approved with further medical input through direct communication with the MHD Hotline.

Type of Criteria: Increased risk of ADE Preferred Drug List
 Appropriate Indications Clinical Edit

Data Sources: Only Administrative Databases Databases + Prescriber-Supplied

Setting & Population

- Drug class for review: Psychotropic medications
- Age range: All appropriate MO HealthNet participants

Approval Criteria

- Demonstrated compliance to prescribed therapy (90 out of 120 days) for participants ≥ 18 years of age who are not enrolled in foster care **OR**
- Participant ≤ 5 years of age: history of ≤ 3 different psychotropic medications in the past 60 days **OR**
- Participant ≥ 6 years of age: history of ≤ 5 different psychotropic medications in the past 60 days
- Documented diagnosis of a seizure disorder: all seizure medications are not counted in a participant’s past history of psychotropic medications

Denial Criteria

- Therapy will be denied if all approval criteria are not met

Required Documentation

Laboratory Results:
MedWatch Form:

Progress Notes:
Other:

Disposition of Edit

Denial: Exception code "1010" (Therapeutic Duplication)
Rule Type: CE

Default Approval Period

3 months

Appendix A – Agents in the Psychotropic Medications Polypharmacy Clinical Edit

| Psychotropic Medications |
|--------------------------------------|
| ALPRAZOLAM |
| AMITRIPTYLINE HCL |
| AMITRIPTYLINE/CHLORDIAZEPOXIDE |
| AMOBARBITAL SODIUM |
| AMOXAPINE |
| AMPHETAMINE |
| AMPHETAMINE SULFATE |
| ARIPIPRAZOLE |
| ARIPIPRAZOLE LAUROXIL |
| ARIPIPRAZOLE LAUROXIL, SUBMICRONIZED |
| ARMODAFINIL |
| AZENAPINE |
| AZENAPINE MALEATE |
| ATOMOXETINE HCL |
| BREMELANOTIDE ACETATE |
| BREXPIPRAZOLE |
| BRIVARACETAM |
| BUPROPION HBR |
| BUPROPION HCL |
| BUSPIRONE HCL |
| CANNABIDIOL (CBD) |
| CARBAMAZEPINE |
| CARIPRAZINE HCL |
| CENOBAMATE |
| CHLORDIAZEPOXIDE HCL |
| CHLORDIAZEPOXIDE/CLIDINIUM BR |

SmartPA Clinical Proposal Form

© 2023 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

| Psychotropic Medications continued |
|---|
| CHLORPROMAZINE HCL |
| CITALOPRAM HYDROBROMIDE |
| CLOBAZAM |
| CLOMIPRAMINE HCL |
| CLONAZEPAM |
| CLONIDINE HCL |
| CLORAZEPATE DIPOTASSIUM |
| CLOZAPINE |
| DARIDOREXANT HCL |
| DESIPRAMINE HCL |
| DESVENLAFAXINE |
| DESVENLAFAXINE SUCCINATE |
| DEUTETRABENAZINE |
| DEXMEDETOMIDINE HCL |
| DEXMETHYLPHENIDATE HCL |
| DEXTROAMPHETAMINE |
| DEXTROAMPHETAMINE SULFATE |
| DEXTROAMPHETAMINE/AMPHETAMINE |
| DEXTROMETHORPHAN HBR/BUPROPION HCL |
| DEXTROMETHORPHAN HBR/QUINIDINE SULFATE |
| DIAZEPAM |
| DIVALPROEX SODIUM |
| DOXEPIN HCL |
| DROPERIDOL |
| DULOXETINE HCL |
| ESCITALOPRAM OXALATE |
| ESKETAMINE HCL |
| ESLICARBAZEPINE ACETATE |
| ESTAZOLAM |
| ESZOPICLONE |
| ETHOSUXIMIDE |
| ETHOTOIN |
| FELBAMATE |
| FENFLURAMINE HCL |
| FLIBANSERIN |
| FLUOXETINE HCL |
| FLUPHENAZINE DECANOATE |
| FLUPHENAZINE HCL |
| FLURAZEPAM HCL |
| FLUVOXAMINE MALEATE |
| FOSPHENYTOIN SODIUM |
| GABAPENTIN |
| GABAPENTIN ENACARBIL |
| GABAPENTIN/LIDOCAINE |
| GABAPENTIN/LIDOCAINE HCL/GAUZE BANDAGE/S |
| GABAPENTIN/LIDOCAINE HCL/MENTHOL |
| GABAPENTIN/LIDOCAINE HCL/SILICONE ADHESI |

| Psychotropic Medications continued |
|---|
| GABAPENTIN/LIDOCAINE/PRILOCAINE/TRANSPAR |
| GANAXOLONE |
| GUANFACINE HCL |
| HALOPERIDOL |
| HALOPERIDOL DECANOATE |
| HALOPERIDOL LACTATE |
| ILOPERIDONE |
| IMIPRAMINE HCL |
| IMIPRAMINE PAMOATE |
| ISOCARBOXAZID |
| LACOSAMIDE |
| LAMOTRIGINE |
| LEMBOREXANT |
| LEVETIRACETAM |
| LEVETIRACETAM IN NACL (ISO-OS) |
| LEVOMILNACIPRAN HCL |
| LISDEXAMFETAMINE DIMESYLATE |
| LITHIUM CARBONATE |
| LITHIUM CITRATE |
| LORAZEPAM |
| LOXAPINE |
| LOXAPINE SUCCINATE |
| LUMATEPERONE TOSYLATE |
| LURASIDONE HCL |
| MAPROTILINE HCL |
| MEPROBAMATE |
| METHAMPHETAMINE HCL |
| METHSUXIMIDE |
| METHYLPHENIDATE |
| METHYLPHENIDATE HCL |
| MIDAZOLAM |
| MIDAZOLAM HCL |
| MIDAZOLAM/KETAMINE HCL/ONDANSETRON HCL |
| MILNACIPRAN HCL |
| MIRTAZAPINE |
| MODAFINIL |
| MOLINDONE HCL |
| NEFAZODONE HCL |
| NORTRIPTYLINE HCL |
| OLANZAPINE |
| OLANZAPINE PAMOATE |
| OLANZAPINE/FLUOXETINE HCL |
| OLANZAPINE/SAMIDORPHAN MALATE |
| OXAZEPAM |
| OXCARBAZEPINE |
| PALIPERIDONE |
| PALIPERIDONE PALMITATE |

SmartPA Clinical Proposal Form

© 2023 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

| Psychotropic Medications continued |
|---|
| PAROXETINE HCL |
| PAROXETINE MESYLATE |
| PENTOBARBITAL SODIUM |
| PERAMPANEL |
| PERPHENAZINE |
| PERPHENAZINE/AMITRIPTYLINE HCL |
| PHENELZINE SULFATE |
| PHENOBARBITAL |
| PHENOBARBITAL SODIUM |
| PHENYTOIN |
| PHENYTOIN SODIUM |
| PHENYTOIN SODIUM EXTENDED |
| PIMAVANSERIN TARTRATE |
| PIMOZIDE |
| PITOLISANT HCL |
| PREGABALIN |
| PRIMIDONE |
| PROTRIPTYLINE HCL |
| QUAZEPAM |
| QUETIAPINE FUMARATE |
| RAMELTEON |
| RISPERIDONE |
| RISPERIDONE MICROSPHERES |
| RUFINAMIDE |
| SECOBARBITAL SODIUM |
| SELEGILINE |
| SERDEXMETHYLPHEN/DEXMETHYLPHEN |
| SERTRALINE HCL |
| SODIUM OXYBATE |
| SODIUM OXYBATE/CALCIUM OXYBATE/MAGNESIUM |
| SOLRIAMFETOL HCL |
| STIRIPENTOL |
| SUVOREXANT |
| TASIMELTEON |
| TEMAZEPAM |
| TETRABENAZINE |
| THIORIDAZINE HCL |
| THIOTHIXENE |
| TIAGABINE HCL |
| TOPIRAMATE |
| TRANLYCYPROMINE SULFATE |
| TRAZODONE HCL |
| TRIAZOLAM |
| TRIFLUOPERAZINE HCL |
| TRIMIPRAMINE MALEATE |
| VALBENAZINE TOSYLATE |

| Psychotropic Medications continued |
|---|
| VALPROIC ACID |
| VALPROIC ACID (AS SODIUM SALT) |
| VENLAFAXINE BESYLATE |
| VENLAFAXINE HCL |
| VIGABATRIN |
| VILAZODONE HCL |
| VILOXAZINE HCL |
| VORTIOXETINE HYDROBROMIDE |
| ZALEPLON |
| ZIPRASIDONE HCL |
| ZIPRASIDONE MESYLATE |
| ZOLPIDEM TARTRATE |
| ZONISAMIDE |

DRAFT